DLL4 and neoplasm: However the reduction of DLL4 expression in vessels was not prominent in mDLL4-tumours treated with DBZ, bevacizumab or combination (V, VIII and XI), suggesting the enhanced expression of endogenous DLL4 by mDLL4 was more resistant to reversal by DBZ.